Bristol-Myers Squibb Videx receives HIV treatment monotherapy indication.
Executive Summary
BRISTOL-MYERS SQUIBB VIDEX RECEIVES MONOTHERAPY INDICATION, becoming the first nucleoside analog to compete with Glaxo Wellcome's Retrovir for first-line use. Videx (didanosine, ddI) was approved for the expanded indication on July 17, but labeling for the use was only recently finalized.